Literature DB >> 21703822

A study of performance on microarray data sets for a classifier based on information theoretic learning.

Iago Porto-Díaz1, Verónica Bolón-Canedo, Amparo Alonso-Betanzos, Oscar Fontenla-Romero.   

Abstract

Gene-expression microarray is a novel technology that allows the examination of tens of thousands of genes at a time. For this reason, manual observation is not feasible and machine learning methods are progressing to face these new data. Specifically, since the number of genes is very high, feature selection methods have proven valuable to deal with these unbalanced-high dimensionality and low cardinality-data sets. In this work, the FVQIT (Frontier Vector Quantization using Information Theory) classifier is employed to classify twelve DNA gene-expression microarray data sets of different kinds of cancer. A comparative study with other well-known classifiers is performed. The proposed approach shows competitive results outperforming all other classifiers.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703822     DOI: 10.1016/j.neunet.2011.05.010

Source DB:  PubMed          Journal:  Neural Netw        ISSN: 0893-6080


  3 in total

1.  A new DNA sequence entropy-based Kullback-Leibler algorithm for gene clustering.

Authors:  Houshang Dehghanzadeh; Mostafa Ghaderi-Zefrehei; Seyed Ziaeddin Mirhoseini; Saeid Esmaeilkhaniyan; Ishaku Lemu Haruna; Hamed Amirpour Najafabadi
Journal:  J Appl Genet       Date:  2020-01-24       Impact factor: 3.240

2.  Random Subspace Aggregation for Cancer Prediction with Gene Expression Profiles.

Authors:  Liying Yang; Zhimin Liu; Xiguo Yuan; Jianhua Wei; Junying Zhang
Journal:  Biomed Res Int       Date:  2016-11-24       Impact factor: 3.411

3.  CD109 plays a role in osteoclastogenesis.

Authors:  Yongqiang Wang; Maayan Inger; Hongwei Jiang; Howard Tenenbaum; Michael Glogauer
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.